Wiggins CM - Search Results

1

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics.

Gillings AS, Balmanno K, Wiggins CM, Johnson M, Cook SJ. Gillings AS, et al. Among authors: wiggins cm. FEBS J. 2009 Nov;276(21):6050-62. doi: 10.1111/j.1742-4658.2009.07329.x. Epub 2009 Sep 29. FEBS J. 2009. PMID: 19788418 Free article. Review.

2

ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL.

Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, Degenhardt K, White E, Cook SJ. Ewings KE, et al. Among authors: wiggins cm. EMBO J. 2007 Jun 20;26(12):2856-67. doi: 10.1038/sj.emboj.7601723. Epub 2007 May 24. EMBO J. 2007. PMID: 17525735 Free PMC article.

3

Bim and the pro-survival Bcl-2 proteins: opposites attract, ERK repels.

Ewings KE, Wiggins CM, Cook SJ. Ewings KE, et al. Among authors: wiggins cm. Cell Cycle. 2007 Sep 15;6(18):2236-40. doi: 10.4161/cc.6.18.4728. Epub 2007 Jul 10. Cell Cycle. 2007. PMID: 17881896 Review.

4

Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM.

Wiggins CM, Johnson M, Cook SJ. Wiggins CM, et al. Cell Signal. 2010 May;22(5):801-8. doi: 10.1016/j.cellsig.2010.01.004. Epub 2010 Jan 13. Cell Signal. 2010. PMID: 20074640

5

BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation.

Wiggins CM, Tsvetkov P, Johnson M, Joyce CL, Lamb CA, Bryant NJ, Komander D, Shaul Y, Cook SJ. Wiggins CM, et al. J Cell Sci. 2011 Mar 15;124(Pt 6):969-77. doi: 10.1242/jcs.058438. J Cell Sci. 2011. PMID: 21378313

6

c-Cbl is not required for ERK1/2-dependent degradation of BimEL.

Wiggins CM, Band H, Cook SJ. Wiggins CM, et al. Cell Signal. 2007 Dec;19(12):2605-11. doi: 10.1016/j.cellsig.2007.08.008. Epub 2007 Aug 23. Cell Signal. 2007. PMID: 17884340 Free PMC article.

7

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.

Haagensen EJ, Thomas HD, Mudd C, Tsonou E, Wiggins CM, Maxwell RJ, Moore JD, Newell DR. Haagensen EJ, et al. Among authors: wiggins cm. Eur J Cancer. 2016 Mar;56:69-76. doi: 10.1016/j.ejca.2015.12.012. Epub 2016 Jan 25. Eur J Cancer. 2016. PMID: 26820797

8

A 'synthetic-sickness' screen for senescence re-engagement targets in mutant cancer backgrounds.

Cairney CJ, Godwin LS, Bilsland AE, Burns S, Stevenson KH, McGarry L, Revie J, Moore JD, Wiggins CM, Collinson RS, Mudd C, Tsonou E, Sadaie M, Bennett DC, Narita M, Torrance CJ, Keith WN. Cairney CJ, et al. Among authors: wiggins cm. PLoS Genet. 2017 Aug 14;13(8):e1006942. doi: 10.1371/journal.pgen.1006942. eCollection 2017 Aug. PLoS Genet. 2017. PMID: 28806777 Free PMC article.

9

Development and Characterization of a Modular CRISPR and RNA Aptamer Mediated Base Editing System.

Collantes JC, Tan VM, Xu H, Ruiz-Urigüen M, Alasadi A, Guo J, Tao H, Su C, Tyc KM, Selmi T, Lambourne JJ, Harbottle JA, Stombaugh J, Xing J, Wiggins CM, Jin S. Collantes JC, et al. Among authors: wiggins cm. CRISPR J. 2021 Feb;4(1):58-68. doi: 10.1089/crispr.2020.0035. CRISPR J. 2021. PMID: 33616445 Free PMC article.

10

Expedition medicine--the risk of illness and injury.

Lyon RM, Wiggins CM. Lyon RM, et al. Among authors: wiggins cm. Wilderness Environ Med. 2010 Dec;21(4):318-24. doi: 10.1016/j.wem.2010.09.002. Epub 2010 Sep 21. Wilderness Environ Med. 2010. PMID: 21168784

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page